World Health Organization. (2023). Epilepsy: A public health imperative. Geneva: WHO Press.
[2]
International League Against Epilepsy. (2023). Classification of the Epilepsies. Epilepsia Journal.
[3]
American Academy of Neurology. (2022). Practice guideline update: Antiepileptic drugs for absence seizures. Neurology Journal.
[4]
Kasper, D.L., et al. (2022). Harrison's Principles of Internal Medicine, 21st Edition. McGraw-Hill Education.
[5]
Fisher, R.S., et al. (2017). Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia Journal.
[6]
National Institute for Health and Care Excellence. (2023). Epilepsy: Diagnosis and management. NICE Guidelines.
[7]
Berg, A.T., et al. (2021). The etiologies of epilepsy. In: Engel J, Pedley TA, editors. Epilepsy: A Comprehensive Textbook, 3rd Edition. Lippincott Williams & Wilkins.
[8]
Glauser, T.A., et al. (2013). Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New England Journal of Medicine.
[9]
Perucca, P., et al. (2022). Pharmacological management of absence seizures. Expert Opinion on Pharmacotherapy.
[10]
Wirrell, E.C. (2020). Absence epilepsy: Continuum of clinical features and terminology. Epilepsy Currents Journal.